U.S. Department of Health & Human Services
Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report
Institute for Clinical and Economic Review, issuing body. Midwest Comparative Effectiveness Public Advisory Council, issuing body.
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Androgen Antagonists -- therapeutic use
Prostatic Neoplasms -- drug therapy
Androgen Antagonists -- adverse effects
Randomized Controlled Trials as Topic
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license.
1 online resource (1 PDF file (various pagings))
NLM Unique ID:
See catalog record
Metadata (Dublin Core)